Concert Pharma

CNCE NASDAQ
9.71
-0.27
-2.71%
盘后: 9.71 0 0.00% 16:00 08/23 EDT
开盘
9.96
昨收
9.98
最高
10.01
最低
9.55
成交量
12.80万
成交均量(3M)
18.62万
52周最高
17.83
52周最低
9.21
换手率
0.54%
市值
2.31亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Concert Pharma CNCE股票价格,Concert Pharma股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
展开 >

最近浏览

名称
价格
涨跌幅